New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, USA.
Stevenson
Takyiah
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003270:Contraceptive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069448:Denosumab; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009277:Nandrolone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D053245:RANK Ligand / Q000009:adverse effects / Q000819:agonists / Q000627:therapeutic use*; D012597:Sclerosing Solutions / Q000009:adverse effects / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003270:Contraceptive Agents; D053245:RANK Ligand; D012597:Sclerosing Solutions; C505688:TNFSF11 protein, human; D000077423:Polidocanol; D011092:Polyethylene Glycols; C023635:dienogest; D000069448:Denosumab; D004958:Estradiol; D009277:Nandrolone